Preclinical evaluation of a natural extract-based oral nanoformulation from Eucalyptus tereticornis for potential use in treating type 2 diabetes mellitus.

The acute, subacute, and subchronic oral toxicities, as well as the combined chronic toxicity and carcinogenicity, of a nanotechnology-based formulation derived from a natural extract of Eucalyptus tereticornis leaves were investigated. This nanoformulation demonstrates anti-obesogenic and potentially anti-diabetic properties. Our study aims to conduct preclinical tests to evaluate the chemical formulation. To assess acute toxicity, rats received a single oral dose of 2000 mg/kg of the nanoformulation. In the subacute trial, mice were treated with approximately 1180 mg/kg of the nanoformulation for 28 days. In the combined chronic toxicity and carcinogenicity study, the nanoformulation was administered daily at approximately 590 mg/kg for 10 months. At the end of the experiment, hematological, biochemical, and histopathological assessments were conducted. Throughout the acute, subacute, subchronic, and chronic/carcinogenicity studies, animals showed no toxic effects from the treatment or the vehicle. No histopathological lesions, such as degeneration or cell death in the liver, kidney, or gastrointestinal tract, were observed. Treatments did not cause any clinical changes, and there were no significant differences in weight, hematological, or biochemical parameters. Therefore, the nanoformulation did not produce toxic effects in the animals.